205 related articles for article (PubMed ID: 24831836)
1. Development and validation of a fully GMP-compliant production process of autologous, tumor-lysate-pulsed dendritic cells.
Eyrich M; Schreiber SC; Rachor J; Krauss J; Pauwels F; Hain J; Wölfl M; Lutz MB; de Vleeschouwer S; Schlegel PG; Van Gool SW
Cytotherapy; 2014 Jul; 16(7):946-64. PubMed ID: 24831836
[TBL] [Abstract][Full Text] [Related]
2. Large-scale immunomagnetic selection of CD14+ monocytes to generate dendritic cells for cancer immunotherapy: a phase I study.
Babatz J; Röllig C; Oelschlägel U; Zhao S; Ehninger G; Schmitz M; Bornhäuser M
J Hematother Stem Cell Res; 2003 Oct; 12(5):515-23. PubMed ID: 14594508
[TBL] [Abstract][Full Text] [Related]
3. Isolation of monocytes from leukapheretic products for large-scale GMP-grade generation of cytomegalovirus-specific T-cell lines by means of an automated elutriation device.
Perseghin P; D'Amico G; Dander E; Gaipa G; Dassi M; Biagi E; Biondi A
Transfusion; 2008 Aug; 48(8):1644-9. PubMed ID: 18513258
[TBL] [Abstract][Full Text] [Related]
4. Closing the manufacturing process of dendritic cell vaccines transduced with adenovirus vectors.
Gulen D; Abe F; Maas S; Reed E; Cowan K; Pirruccello S; Wisecarver J; Warkentin P; Northam M; Turken O; Coskun U; Senesac J; Talmadge JE
Int Immunopharmacol; 2008 Dec; 8(13-14):1728-36. PubMed ID: 18793758
[TBL] [Abstract][Full Text] [Related]
5. Effective clinical-scale production of dendritic cell vaccines by monocyte elutriation directly in medium, subsequent culture in bags and final antigen loading using peptides or RNA transfection.
Erdmann M; Dörrie J; Schaft N; Strasser E; Hendelmeier M; Kämpgen E; Schuler G; Schuler-Thurner B
J Immunother; 2007 Sep; 30(6):663-74. PubMed ID: 17667530
[TBL] [Abstract][Full Text] [Related]
6. Induction of cytolytic T lymphocytes against pediatric solid tumors in vitro using autologous dendritic cells pulsed with necrotic primary tumor.
Shilyansky J; Jacobs P; Doffek K; Sugg SL
J Pediatr Surg; 2007 Jan; 42(1):54-61; discussion 61. PubMed ID: 17208541
[TBL] [Abstract][Full Text] [Related]
7. Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy.
Curti A; Isidori A; Ferri E; Terragna C; Neyroz P; Cellini C; Ratta M; Baccarani M; Lemoli RM
Leuk Lymphoma; 2004 Jul; 45(7):1419-28. PubMed ID: 15359643
[TBL] [Abstract][Full Text] [Related]
8. Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70.
Zobywalski A; Javorovic M; Frankenberger B; Pohla H; Kremmer E; Bigalke I; Schendel DJ
J Transl Med; 2007 Apr; 5():18. PubMed ID: 17430585
[TBL] [Abstract][Full Text] [Related]
9. Comparison of alpha-Type-1 polarizing and standard dendritic cell cytokine cocktail for maturation of therapeutic monocyte-derived dendritic cell preparations from cancer patients.
Trepiakas R; Pedersen AE; Met O; Hansen MH; Berntsen A; Svane IM
Vaccine; 2008 Jun; 26(23):2824-32. PubMed ID: 18450338
[TBL] [Abstract][Full Text] [Related]
10. An accelerated, clinical-grade protocol to generate high yields of type 1-polarizing messenger RNA-loaded dendritic cells for cancer vaccination.
Brabants E; Heyns K; De Smet S; Devreker P; Ingels J; De Cabooter N; Debacker V; Dullaers M; VAN Meerbeeck JP; Vandekerckhove B; Vermaelen KY
Cytotherapy; 2018 Sep; 20(9):1164-1181. PubMed ID: 30122654
[TBL] [Abstract][Full Text] [Related]
11. A functional comparison of mature human dendritic cells prepared in fluorinated ethylene-propylene bags or polystyrene flasks.
Kurlander RJ; Tawab A; Fan Y; Carter CS; Read EJ
Transfusion; 2006 Sep; 46(9):1494-504. PubMed ID: 16965575
[TBL] [Abstract][Full Text] [Related]
12. Generation of immature autologous clinical grade dendritic cells for vaccination of cancer patients.
Toungouz M; Quinet C; Thille E; Fourez S; Pradier O; Delville JP; Velu T; Lambermont M
Cytotherapy; 1999; 1(6):447-53. PubMed ID: 20426545
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
14. Leukoreduction system chambers are an efficient, valid, and economic source of functional monocyte-derived dendritic cells and lymphocytes.
Pfeiffer IA; Zinser E; Strasser E; Stein MF; Dörrie J; Schaft N; Steinkasserer A; Knippertz I
Immunobiology; 2013 Nov; 218(11):1392-401. PubMed ID: 23932569
[TBL] [Abstract][Full Text] [Related]
15. Dendritic Cells Generated in the Presence of Platelet Lysate Have a Reduced Type 1 Polarization Capacity.
Tešić N; Pekle Simonič I; Roškar K; Rožman P; Švajger U
Immunol Invest; 2020 Apr; 49(3):215-231. PubMed ID: 31170833
[TBL] [Abstract][Full Text] [Related]
16. Experimental production of clinical-grade dendritic cell vaccine for acute myeloid leukemia.
Tan YF; Sim GC; Habsah A; Leong CF; Cheong SK
Malays J Pathol; 2008 Dec; 30(2):73-9. PubMed ID: 19291915
[TBL] [Abstract][Full Text] [Related]
17. The maturation-dependent production of interleukin-16 is impaired in monocyte-derived dendritic cells from atopic dermatitis patients but is restored by inflammatory cytokines TNF-alpha and IL-1beta.
Reich K; Hugo S; Middel P; Blaschke V; Heine A; Neumann C
Exp Dermatol; 2004 Dec; 13(12):740-7. PubMed ID: 15560757
[TBL] [Abstract][Full Text] [Related]
18. A protocol for generation of clinical grade mRNA-transfected monocyte-derived dendritic cells for cancer vaccines.
Mu LJ; Gaudernack G; Saebøe-Larssen S; Hammerstad H; Tierens A; Kvalheim G
Scand J Immunol; 2003 Nov; 58(5):578-86. PubMed ID: 14629630
[TBL] [Abstract][Full Text] [Related]
19. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression.
Geiger JD; Hutchinson RJ; Hohenkirk LF; McKenna EA; Yanik GA; Levine JE; Chang AE; Braun TM; Mulé JJ
Cancer Res; 2001 Dec; 61(23):8513-9. PubMed ID: 11731436
[TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis factor alpha and CD40 ligand antagonize the inhibitory effects of interleukin 10 on T-cell stimulatory capacity of dendritic cells.
Brossart P; Zobywalski A; Grünebach F; Behnke L; Stuhler G; Reichardt VL; Kanz L; Brugger W
Cancer Res; 2000 Aug; 60(16):4485-92. PubMed ID: 10969796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
